Clinical Focus

  • Pediatric Hematology-Oncology

Academic Appointments

Administrative Appointments

  • Medical Director, Stanford Pediatric Stem Cell Transplantation (2025 - Present)

Professional Education

  • Medical Education: Creighton University School of Medicine Registrar (2019) NE
  • Board Certification: American Board of Pediatrics, Pediatric Hematology-Oncology (2017)
  • Fellowship: St Jude Children's Research Hospital Bone Marrow Transplant and Cellular Therapy Fellowshop (2016) TN
  • Fellowship: University of Minnesota Pediatric Hematology/Oncology Fellowship (2015) MN
  • Board Certification: American Board of Pediatrics, Pediatrics (2012)
  • Residency: Stanford University Pediatric Residency at Lucile Packard Children's Hospital (2012) CA

Contact

  • Academic
    jlalex@stanford.edu
    Department: Pediatrics - Ped Stem Cell Transplantation Position: Clinical Associate Professor
  • Clinical (Primary)  Pediatric Stem Cell Transplantation 725 Welch Rd Ste 160 Palo Alto, CA 94304 (650) 497-8959 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5798

Clinical Trials

  • A Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) Recruiting

    The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.

    View full details

  • BMT 382 - FOXP3 IND Trial Recruiting

    This first-in-human, Phase 1 clinical trial will test the feasibility of the manufacturing and the safety of the administration of CD4\^LVFOXP3 in up to 30 evaluable human participants with IPEX and evaluate the impact of the CD4\^LVFOXP3 infusion on the disease.

    View full details

  • Phase I/II ViralSpecific T-Lymphocytes by CytokineCaptureSystem to Treat Adenovirus/CMV/EBV afterHCT Recruiting

    The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenovirus, CMV, and EBV, in subjects who have previously received any type of allogeneic HCT or solid organ transplant (SOT), or have compromised immunity. Reconstitution of anti-viral immunity by donor-derived cytotoxic T lymphocytes has shown promise in preventing and treating infections with adenovirus, CMV, and EBV. However, the weeks taken to prepare patient-specific products, and cost associated with products that may not be used limits their value. In this trial, we will evaluate viral specific T cells generated by gamma capture technology. Eligible patients will include HCT and/or SOT recipients, and/or patients with compromised immunity who have adenovirus, CMV, or EBV infection or refractory viremia that is persistent despite standard therapy. Infusion of the cellular product will be assessed for safety and efficacy.

    View full details

  • Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease Not Recruiting

    This research study is investigating whether alpha beta T-cell depleted hematopoietic stem cell transplant (HSCT) can be an immune system replacement for Crohn disease patients and whether this is safe and effective for patients with early onset, medically refractory Crohn disease.

    Stanford is currently not accepting patients for this trial.

    View full details

All Publications

  • Hematopoietic Cell Transplantation for Wiskott-Aldrich syndrome: A PIDTC Report. Blood advances Alexander, J. L., Dávila Saldaña, B. J., Brazauskas, R., Dammalapati, S. G., Griffith, L. M., Shah, A. J., Shimano, K. A., Ochs, H. D., Bleesing, J., Ebens, C. L., Kapadia, M., Bauchat, A., Kapoor, N., Oved, J. H., Eissa, H., Lust, H., Keller, M. D., Haines, H., Chandrakasan, S., Talano, J. M., Rayes, A., Madden, L. M., Shereck, E. B., Miller, H. K., Forbes Satter, L. R., Martinez, C. A., Rozmus, J., Bednarski, J. J., Yu, L. C., Chellapandian, D., Aquino, V. M., Knutsen, A. P., Chong, H., Chopek, A., Gillio, A. P., Joshi, A., Rangarajan, H. G., Moore, T. B., Andolina, J. R., DeSantes, K., Vander Lugt, M. T., Prockop, S. E., Shyr, D., Sullivan, K. E., Parikh, S. H., Weinacht, K. G., Torgerson, T. R., Marsh, R. A., Dvorak, C. C., Chan, A. Y., Haddad, E., Heimall, J., Pulsipher, M. A., Leiding, J. W., Kohn, D. B., Puck, J. M., Notarangelo, L. D., Rawlings, D. J., Cowan, M. J., Petrovic, A., Pai, S. Y., Burroughs, L. M. 2025

    Abstract

    Wiskott-Aldrich syndrome (WAS), an X-linked disorder characterized by immunodeficiency, thrombocytopenia, autoimmunity, and malignancy, can be effectively treated with allogeneic hematopoietic cell transplantation (HCT). Older age at HCT and mismatched donors are known to impact overall survival (OS). The influence of specific clinical manifestations or WAS variant class on OS and factors associated with event-free survival (EFS) remain incompletely defined. We analyzed outcomes of 308 patients with WAS who underwent HCT at 37 institutions of the Primary Immune Deficiency Treatment Consortium (PIDTC) from 1990-2018. With a median follow-up of 5.3 years, the 5-year OS and EFS were 87.2% and 79.7%, respectively. Age ≥5 years, donor type, and a pre-HCT history of severe infection had a negative impact on OS and EFS, whereas pre-HCT autoimmunity had no impact. Reduced intensity regimens were associated with lower T cell and myeloid donor chimerism, particularly when non-busulfan-based regimens were used. Low myeloid donor chimerism was associated with lower platelet counts. Mixed chimerism was not consistently associated with post-HCT autoimmunity. Patients with class I (exon 1-2 missense and intron 5 hotspot variants) and class II variants (all others) had similar pre-HCT clinical symptom severity and no difference in OS, EFS or platelet recovery post-HCT. In conclusion, our study showed excellent long-term OS and EFS following HCT for WAS, highlighting the importance of early HCT, before the development of severe infections. We confirmed that HCT using busulfan-based conditioning was associated with improved donor chimerism and platelet recovery. This study was registered at www.clinicaltrials.gov as #NCT02064933.

    View details for DOI 10.1182/bloodadvances.2025017662

    View details for PubMedID 41346295

  • Outcomes Following Matched Sibling Donor Transplantation for Severe Combined Immunodeficiency: A Report from the PIDTC. Blood advances Rayes, A., Logan, B. R., Liu, X., Dara, J., Buckley, R. H., Oved, J. H., Kapoor, N., Kapadia, M., Chandra, S., Martinez, C. A., Bunin, N., Chandrakasan, S., Chen, K., Bednarski, J. J., Haines, H. L., Eissa, H., Talano, J. M., Keller, M. D., Ebens, C. L., Chaudhury, S., Shereck, E. B., Aquino, V. M., Knutsen, A. P., Alexander, J. L., Gillio, A. P., Chellapandian, D., Shah, A. J., Miller, H. K., Vander Lugt, M. T., Seroogy, C. M., Dorsey, M. J., Mousallem, T., Parrott, R. E., O'Reilly, R. J., Aguayo-Hiraldo, P. I., Prockop, S. E., Dávila Saldaña, B. J., Thakar, M. S., Burroughs, L. M., Torgerson, T. R., Leiding, J. W., Marsh, R. A., Griffith, L. M., Pulsipher, M. A., Kohn, D. B., Notarangelo, L. D., Cowan, M. J., Puck, J. M., Cuvelier, G. D., Heimall, J., Haddad, E., Pai, S. Y., Dvorak, C. C. 2025

    Abstract

    The Primary Immune Deficiency Treatment Consortium (PIDTC) performed a retrospective analysis of 133 patients with severe combined immunodeficiency (SCID) receiving matched sibling donor (MSD) hematopoietic cell transplantation (HCT) between 1980 and 2023 at 30 North American institutions. In this largest cohort of MSD outcomes in SCID patients to date, we examined the impact of conditioning regimen and graft-versus-host disease (GVHD) prophylaxis on survival and immune recovery. Outcomes after MSD HCT for SCID were excellent. Patients without an active infection or failure to thrive (FTT) at the time of HCT had 5-year overall survival (OS) superior to those with infection or FTT. Acute and chronic GVHD outcomes were independent of GVHD prophylaxis, conditioning regimen, SCID type, or presence of maternal engraftment. Patients without active infection at the time of HCT had superior chronic GVHD free event-free survival vs. those with infection. T cell reconstitution at 6 months was less likely achieved with use of GVHD prophylaxis or serotherapy, and in leaky SCID or Omenn syndrome patients. At 6 months, 1 year, and 2-5 years T cell reconstitution was less likely with ADA, DCLRE1C or RAG genotype. B cell reconstitution at 1 year and 2-5 years was negatively impacted by development of grade II-IV or III-IV acute GVHD. Conditioning did not impact T or B cell reconstitution. Our data suggest omitting conditioning and GVHD prophylaxis for patients with typical SCID did not negatively impact 5-year outcomes following MSD HCT, but the data are insufficient to recommend this approach for best long-term outcomes. (ClinicalTrials.gov NCT01186913).

    View details for DOI 10.1182/bloodadvances.2025016812

    View details for PubMedID 41289158

  • Marrow-ly we learn along: A needs assessment of the educational needs of pediatric and young adult patients with bone marrow failure Bowman, S., de Jong, J., Alexander, J., Ilonze, C., Rose, M. ELSEVIER. 2025: 2861-2862

    View details for DOI 10.1182/blood-2025-2861

    View details for Web of Science ID 001659007200010

  • Improvement Across Multi-organ Domains and Patient Reported Outcomes in Refractory Juvenile-Onset Systemic Sclerosis (jSSc) up to 4 Years After Autologous Stem Cell Transplantation (ASCT) Li, J., Horvei, P., Rosser, F., Rose-Felker, K., Sood, V., Olson, A., Vandergrift, V., Hogue, N., Farver, L., Mcguire, D., Havrilla, H., Alexander, J., McIntyre, S., Szabolcs, P., Torok, K. WILEY. 2024: 4985-4988

    View details for Web of Science ID 001331419107227

  • Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT) Torok, K., Horvei, P., Rosser, F., Rose-Felker, K., Sood, V., Olsen, A., Hogue, N., Vandergrift, V., Farver, L., Mcguire, D., Li, J., Havrilla, H., Alexander, J., McIntyre, S., Szabolcs, P. WILEY. 2023: 5204-5206

    View details for Web of Science ID 001190014305212